haberturk.com
Negativehaberturk.com · · TR
GLP-1 ilaçları için yeni bir görme kaybı uyarısı yayınlandı
Executive Summary
AI-generatedThe U.S. Food and Drug Administration (FDA) has mandated new safety warnings for popular GLP-1 drugs, including Ozempic and Mounjaro, due to an increased risk of a rare eye condition. This condition, known as Non-arteritic anterior ischemic optic neuropathy (NAION), can cause sudden, permanent vision loss. The warning follows a 2024 study suggesting a higher incidence of NAION in patients using these medications.
Key Insights
- The FDA required updated safety labels for all GLP-1 receptor agonist drugs used for diabetes and weight loss.
- The specific risk identified is NAION, an eye disorder characterized by sudden, painless vision loss, usually affecting one eye.
- A 2024 study indicated that individuals using GLP-1 drugs had an average of 6.4 NAION cases per 100,000 annually, compared to 3.8 in control groups.
- The condition is particularly concerning as there is no known treatment to restore lost vision.
- Novo Nordisk, a manufacturer of GLP-1 drugs, has publicly stated that existing research does not confirm a causal link between the drugs and NAION.
Topic context
The full article is on the original publisher site.